Exogen Biotechnology, Inc.

Exogen Biotechnology is a Berkeley-based healthcare startup dedicated to quantifying DNA damage and assessing cellular DNA repair capacities. Over 40% of the US population will be diagnosed with cancer and doctors desperately need a way to identify at risk cancer patients and stratify cancer patients for various treatment options. Exogen Bio has developed a technology capable of identifying novel DNA prognostic markers that allows clinicians to better prevent and treat cancer.

Capio Biosciences

Our Vision: To be the world’s leading liquid biopsy company providing valuable clinical information to improve patient outcomes. Founded in 2015 by cofounders Seungpyo Hong PhD (UW, Madison WI) and Andrew Wang MD (UNC, Chapel Hill NC), Capio Biosciences is a biotech start-up focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. At Capio Biosciences we are currently developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.

CARTO Technologies

We make interactive virtual screens for surgical collaboration that you can place anywhere. We use augmented reality to enhance image guided interventions with intuitive imaging displays and machine learning tools.

Bon Opus Biosciences

Bon Opus is a leading supplier of life science products and custom services. Our outstanding services include custom assay development and screening, custom peptide synthesis, custom antibody production, and antibody production. Our array of high quality products include Catalog Antibodies, LinkLight™ Cell Lines, ELISA Kits and Reagents, and Recombinant Proteins. Bon Opus is derived from the Latin Bonum Opus, meaning “good work”. Opus does not simply mean manual labor, it describes creativity and discovery, as with a work of art or music. We’ve built a boutique for scientists who realize bioscience is an art in its own right, where we can provide them with quality reagents, tailored services, and a collaborative partnership. We hope that their good work leads to great discoveries! In today’s culture of mega-corporations, it is easy to feel dwarfed by colossal reagent companies. We know what it is like to feel invisible to representatives who seem like they’re on a completely different plane of existence; as if you’re just a number to them. Bon Opus retains its faith in the sciences, and knows that this only hinders the research of our fellow scientists at every level. We have dedicated ourselves to use our boutique size to be the trusted choice of researchers, and to keep ourselves on par with you, so we can work closely to provide the most customized service possible.

CombImmune

CombImmune is a medical oncology and diagnostic company which intends to design and market novel immunotherapeutic and diagnostic tools related to the oncology and hematology marketplace. CombImmune represents a new paradigm in immunotherapy drug-development as well as diagnostic tumor-type prognostication. CombImmune's mission is to utilize prognostic and predictive biomarkers which inform us about the immune dysfunction to the tumor infilitration in combination with therapeutics which restore immune function and destruction of the tumor.